Incyte
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)
- Conditions
- Chronic Graft Vs. Host Disease
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05544032
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 103
- Registration Number
- NCT05456529
- Locations
- ๐บ๐ธ
Arkansas Research Trials, North Little Rock, Arkansas, United States
๐บ๐ธFirst Oc Dermatology, Fountain Valley, California, United States
๐บ๐ธDermatology Research Associates, Los Angeles, California, United States
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
- Conditions
- Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 82
- Registration Number
- NCT05429268
- Locations
- ๐ง๐ฌ
Medical University Plovdiv, Plovdiv, Bulgaria
๐ง๐ฌAcibadem Cityclinica Mhat Tokuda, Sofia, Bulgaria
๐ง๐ฌUmhat Alexandrovska Sofia, Sofia, Bulgaria
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT05267106
- Locations
- ๐บ๐ธ
Valkyrie Clinical Trials, Beverly Hills, California, United States
๐บ๐ธCity of Hope National Medical Center, Duarte, California, United States
๐บ๐ธProvidence Medical Foundation, Fullerton, California, United States
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT05253807
- Locations
- ๐บ๐ธ
Valkyrie Clinical Trials, Los Angeles, California, United States
๐บ๐ธFlorida Cancer Specialists & Research Institute, Fort Myers, Florida, United States
๐บ๐ธMiami Cancer Institute, Miami, Florida, United States
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
- Conditions
- Vitiligo
- Interventions
- Device: NB-UVB phototherapy
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 55
- Registration Number
- NCT05247489
- Locations
- ๐บ๐ธ
First Oc Dermatology, Fountain Valley, California, United States
๐บ๐ธUC Davis Health, Sacramento, California, United States
๐บ๐ธPalo Alto Medical Foundation, Sunnyvale, California, United States
Study of INCB123667 in Subjects With Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 604
- Registration Number
- NCT05238922
- Locations
- ๐บ๐ธ
City of Hope Medical Center, Duarte, California, United States
๐บ๐ธCity of Hope-Lennar Foundation Cancer Center, Irvine, California, United States
๐บ๐ธValkyrie Clinical Trials, Los Angeles, California, United States
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2
- Conditions
- Chronic Hand Eczema (CHE)
- Interventions
- Drug: Vehicle
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05233410
- Locations
- ๐บ๐ธ
University of Alabama Hospital, Birmingham, Alabama, United States
๐บ๐ธMarvel Clinical Research LLC, Huntington Beach, California, United States
๐บ๐ธAdvanced RX Clin Research, Westminster, California, United States
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 53
- Registration Number
- NCT05222555
- Locations
- ๐บ๐ธ
Morristown Memorial Hospital, Morristown, New Jersey, United States
๐บ๐ธTexas Oncology-Baylor Charles A. Sammons Cancer Center - USOR, Dallas, Texas, United States
๐บ๐ธVista Oncology, Olympia, Washington, United States
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05219864
- Locations
- ๐บ๐ธ
Southwest Skin Specialists Phoenix Biltmore, Phoenix, Arizona, United States
๐บ๐ธRaoof Md Encino, Encino, California, United States
๐บ๐ธFirst Oc Dermatology, Fountain Valley, California, United States